ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
Marksans Pharma Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The filing details operational and sustainability metrics.
Marksans Pharma Ltd submitted its Annual Report for FY 2025-26. The filing also includes a notice for the 34th Annual General Meeting.
Marksans Pharma Ltd has issued a notice to convene its 34th Annual General Meeting on August 27, 2026. The meeting will be held via video conferencing.
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
Marksans Pharma Ltd will hold a board meeting on August 12, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Ltd. has completed the acquisition of 100% share capital of German entity ABCnow GmbH. This strategic move marks the company's expansion into the German market.
Marksans Pharma Ltd filed its quarterly shareholding pattern as per Regulation 31(1)(b). The report details equity distribution among promoters, institutions, and public shareholders.
Marksans Pharma signed a definitive agreement to acquire ABCnow GmbH for €892,384 (≈ 9.64 Crore INR). The deal, closing by 31 July 2026, gives Marksans a foothold in Europe.